LMF Acquisition Opportunities, Inc. *
PROPOSED BUSINESS COMBINATION: SeaStar Medical, Inc.
ENTERPRISE VALUE: $85 million
ANTICIPATED SYMBOL: tbd
LMF Acquisition Opportunities, Inc. proposes to combine with SeaStar Medical, Inc.
- SeaStar Medical’s Selective Cytopheretic Device (“SCD”) is a patented, cell-directed, extracorporeal immunomodulator that selectively targets activated neutrophils and monocytes to address hyperinflammation.
